enuvaptan (BAY2327949) / Bayer - LARVOL DELTA

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease (clinicaltrials.gov) - P1; N=7; Terminated; Sponsor: Bayer; N=22 ➔ 7; Suspended ➔ Terminated; Trial primary completion date: Aug 2021 ➔ Dec 2020; Terminated

Clinical • Enrollment change • Trial primary completion date • Trial termination • Chronic Kidney Disease • Nephrology • Renal Disease • MRI

ASSESS-CKD: A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels. (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Bayer; N=120 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

ASSESS-CKD: A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels. (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Bayer; Trial completion date: Nov 2021 ➔ May 2022; Initiation date: Jan 2021 ➔ May 2021; Trial primary completion date: Oct 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease (clinicaltrials.gov) - P1; N=22; Suspended; Sponsor: Bayer; Recruiting ➔ Suspended

Clinical • Trial suspension • Chronic Kidney Disease • Nephrology • Renal Disease • MRI

ASSESS-CKD: A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels. (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Bayer

Clinical • New P2 trial • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease (clinicaltrials.gov) - P1; N=22; Recruiting; Sponsor: Bayer; Trial completion date: Feb 2021 ➔ Jun 2021; Trial primary completion date: Jan 2021 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Nephrology • Renal Disease • MRI

[VIRTUAL] The Novel Potent and Selective Vasopressin V1a Antagonist BAY2327949 Blocks Arginine Vasopressin-Mediated Decline of Renal Blood Flow and Tissue Oxygenation (KIDNEY WEEK 2020) - "BAY 2327949 is a novel potent and selective vasopressin V1a receptor antagonist blocking the detrimental effects of elevated vasopressin levels on renal perfusion and oxygenation in rats, suggesting potential benefit for patients with cardiorenal diseases. Funding: Commercial Support"

Anesthesia • Nephrology • Renal Disease

[VIRTUAL] Kidney Functional Improvements by a Novel Potent and Selective Vasopressin V1a Antagonist After Ischemia/Reperfusion Injury (I/RI) in Rats (KIDNEY WEEK 2020) - "BAY 2327949 is a novel potent and selective vasopressin V1a receptor antagonist blocking the detrimental effects of elevated vasopressin levels on renal perfusion and oxygenation. For these reasons, BAY 2327949 could become a viable treatment option in conditions of increased AVP levels, such as AKI and CKD. Funding: Commercial Support"

Acute Kidney Injury • Nephrology • Renal Disease • Reperfusion Injury • CST3

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease (clinicaltrials.gov) - P1; N=22; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease • MRI

Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease (clinicaltrials.gov) - P1; N=22; Not yet recruiting; Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed

Clinical • Trial completion • Chronic Kidney Disease • Renal Disease

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status (clinicaltrials.gov) - P1; N=32; Active, not recruiting; Sponsor: Bayer; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: Bayer; Trial completion date: Aug 2020 ➔ May 2020; Trial primary completion date: Jun 2020 ➔ Feb 2020

Clinical • Trial completion date • Trial primary completion date

Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open